# An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

> **NCT00352261** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 80 (—)

## Conditions studied

- Barrett's Esophagus

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT00352261
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 80 (—)
- **Last updated:** 2009-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352261, "An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00352261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*